Literature DB >> 18522953

Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients.

Arata Azuma, Koichi Hagiwara, Shoji Kudoh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18522953     DOI： 10.1164/ajrccm.177.12.1397a

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  9 in total

Review 1.  The Japanese experience with biologic therapies for rheumatoid arthritis.

Authors:  Tsutomu Takeuchi; Hideto Kameda
Journal:  Nat Rev Rheumatol       Date:  2010-09-28       Impact factor: 20.543

Review 2.  Interstital lung disease in ANCA vasculitis.

Authors:  Marco A Alba; Luis Felipe Flores-Suárez; Ashley G Henderson; Hong Xiao; Peiqi Hu; Patrick H Nachman; Ronald J Falk; J Charles Jennette
Journal:  Autoimmun Rev       Date:  2017-05-04       Impact factor: 9.754

3.  Chemotherapy for extensive-stage small-cell lung cancer with idiopathic pulmonary fibrosis.

Authors:  Naohiro Watanabe; Hiroyuki Taniguchi; Yasuhiro Kondoh; Tomoki Kimura; Kensuke Kataoka; Osamu Nishiyama; Masashi Kondo; Yoshinori Hasegawa
Journal:  Int J Clin Oncol       Date:  2013-04-17       Impact factor: 3.402

4.  Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival.

Authors:  Noriyuki Enomoto; Masashi Mikamo; Yoshiyuki Oyama; Masato Kono; Dai Hashimoto; Tomoyuki Fujisawa; Naoki Inui; Yutaro Nakamura; Hideo Yasuda; Akihiko Kato; Soichiro Mimuro; Matsuyuki Doi; Shigehito Sato; Takafumi Suda
Journal:  BMC Pulm Med       Date:  2015-02-22       Impact factor: 3.317

5.  Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival.

Authors:  Nobuhiro Kanaji; Akira Tadokoro; Nobuyuki Kita; Makiko Murota; Tomoya Ishii; Takehiro Takagi; Naoki Watanabe; Yasunori Tojo; Shingo Harada; Yusuke Hasui; Norimitsu Kadowaki; Shuji Bandoh
Journal:  J Cancer Res Clin Oncol       Date:  2016-06-27       Impact factor: 4.553

6.  Combined pulmonary fibrosis and emphysema and idiopathic pulmonary fibrosis in non-small cell lung cancer: impact on survival and acute exacerbation.

Authors:  Sung Woo Moon; Moo Suk Park; Young Sam Kim; Joon Jang; Jae Ho Lee; Choon-Taek Lee; Jin-Haeng Chung; Hyo Sup Shim; Kyung Won Lee; Seung-Seob Kim; Sang Hoon Lee; Ho Il Yoon
Journal:  BMC Pulm Med       Date:  2019-10-15       Impact factor: 3.317

7.  Final safety and efficacy of erlotinib in the phase 4 POLARSTAR surveillance study of 10 708 Japanese patients with non-small-cell lung cancer.

Authors:  Akihiko Gemma; Shoji Kudoh; Masahiko Ando; Yuichiro Ohe; Kazuhiko Nakagawa; Takeshi Johkoh; Naoya Yamazaki; Hiroaki Arakawa; Yoshikazu Inoue; Masahito Ebina; Masahiko Kusumoto; Kazuyoshi Kuwano; Fumikazu Sakai; Hiroyuki Taniguchi; Yuh Fukuda; Akihiro Seki; Tadashi Ishii; Masahiro Fukuoka
Journal:  Cancer Sci       Date:  2014-12       Impact factor: 6.716

8.  Bortezomib therapy-related lung disease in Japanese patients with multiple myeloma: incidence, mortality and clinical characterization.

Authors:  Kazutake Yoshizawa; Harumi Y Mukai; Michiko Miyazawa; Makiko Miyao; Yoshimasa Ogawa; Kazuma Ohyashiki; Takao Katoh; Masahiko Kusumoto; Akihiko Gemma; Fumikazu Sakai; Yukihiko Sugiyama; Kiyohiko Hatake; Yuh Fukuda; Shoji Kudoh
Journal:  Cancer Sci       Date:  2014-01-21       Impact factor: 6.716

9.  Impact of interstitial lung disease on postoperative morbidity and 90-day mortality after pulmonary resection.

Authors:  Weipeng Shao; Jingjing Huang; Hongxiang Feng; Hongliang Sun; Yanhong Ren; Xiaowei Wang; Zhenrong Zhang; Deruo Liu
Journal:  Transl Cancer Res       Date:  2020-02       Impact factor: 1.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.